%PDF-1.4
%
52 0 obj
<>
endobj
49 0 obj
<>
endobj
101 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-03-01T12:34:43Z
2024-03-29T03:36-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-29T03:36-07:00
application/pdf
Heather
2004-150.april
uuid:e5937d7b-1dd1-11b2-0a00-5a0927bd3700
uuid:e5937d7e-1dd1-11b2-0a00-5b0000000000
endstream
endobj
38 0 obj
<>
endobj
39 0 obj
<>
endobj
53 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 28 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 30 0 R/Type/Page>>
endobj
20 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 32 0 R/Type/Page>>
endobj
111 0 obj
[115 0 R]
endobj
112 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
53.964 76.5 m
558.972 76.5 l
S
0 0 0 0 k
52.822 69.665 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
8 0 0 8 53.8216 56.7343 Tm
(746)Tj
ET
0 0 0 0 k
356 69.665 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 56.7343 Tm
(The Journal of Rheumatology 2005; 32:4)Tj
ET
0 0 0 0 k
/GS0 gs
102.631 82.283 407.5 -10.833 re
f*
0.5 w
/GS1 gs
102.631 82.283 407.5 -10.833 re
S
BT
0 0 0 1 k
/T1_1 1 Tf
0.164 Tw 10 0 0 10 53.468 735.6616 Tm
(steroid treatment can partially suppress the tumor growth)Tj
0.02499 Tw 0 -1.2 TD
(and lead to delay in establishing the correct diagnosis.)Tj
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/T1_1 1 Tf
0.0661 Tw 8 0 0 8 53.468 689.6616 Tm
[(The authors are grateful to Prof. Balu )54.9 (Athreya, )17.8 (Thomas Jef)17.7 (ferson Univer-)]TJ
-0.0014 Tw 0 -1.25 TD
[(sity)64.8 (, Philadelphia, Pennsylvania, and the )54.8 (A.I. duPont Hospital for Children,)]TJ
0.19009 Tw T*
[(W)39.8 (ilmington, Delaware, USA, for his thoughtful comments and sugges-)]TJ
0 Tw T*
(tions.)Tj
/T1_2 1 Tf
10 0 0 10 53.468 635.6616 Tm
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 60.468 625.6616 Tm
[(1.)-875.1 (Bohan )54.8 (A, Peter JB. Polymyositis and dermatomyositis \(first of two)]TJ
1.675 -1.25 Td
(parts\). N Engl J Med 1975;292:344-7.)Tj
-1.675 -1.25 Td
[(2.)-875.1 (Sigur)17.7 (geirsson B, Lindel\232f B, Edhag O, )54.8 (Allander E. Risk of cancer)]TJ
1.675 -1.25 Td
[(in patients with dermatomyositis or polymyositis. )54.8 (A)-220.1 (population)]TJ
0 Tc T*
[(based study)65 (. N Engl J Med 1992;326:363-7.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(3.)-875.1 (Chow )17.7 (WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH,)]TJ
1.675 -1.25 Td
[(Fraumeni JF Jr)54.8 (. Cancer risk following polymyositis and)]TJ
T*
(dermatomyositis: a nationwide cohort study in Denmark. Cancer)Tj
T*
(Causes Control 1995;5:9-13.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Hill C, Zhang )36.8 (Y)128.9 (, Sigur)17.7 (geirsson B, et al. Frequency of specific)]TJ
1.675 -1.25 Td
(cancer types in dermatomyositis and polymyositis: a population-)Tj
T*
[(based study)64.9 (. Lancet 2001;357:96-100.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (Y)99.8 (azici )36.8 (Y)128.9 (, Kagen LJ. )17.7 (The association of malignancy with)]TJ
1.675 -1.25 Td
(dermatomyositis. Curr Opin Rheumatol 2000;12:498-500.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (Solomon SD, Maurer KH. )54.8 (Association of dermatomyositis and)]TJ
1.675 -1.25 Td
[(dysgerminoma in a 16-year)19.7 (-old patient. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1983;26:572-3.)Tj
-0.00011 Tc 0.02499 Tw 31.325 33.921 Td
[(7.)-875.1 (Falcini F)79.7 (,)-0.1 ( )17.7 (T)69.9 (accetti G, )17.7 (T)35 (rapani S, Lippi )54.8 (A, Bartolozzi G. )54.8 (Acute)]TJ
1.675 -1.25 Td
(lymphocytic leukemia with dermatomyositis-like onset in)Tj
T*
(childhood [letter]. J Rheumatol 1993;20:1260-1.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (Zantos D, Zhang )36.8 (Y)128.9 (, Felson D. )17.7 (The overall and temporal association)]TJ
1.675 -1.25 Td
(of cancer with polymyositis and dermatomyositis. J Rheumatol)Tj
0 Tc 0 Tw T*
(1994;21:1855-9.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875.1 (Chan )54.8 (A)110.8 (TC, )17.7 (T)69.9 (eo PML, Johnson PJ. Nasopharyngeal carcinoma. )54.8 (Ann)]TJ
0 Tc 1.675 -1.25 Td
(Oncol 2002;13:1007-15.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(10.)-875.1 (A)91.8 (yan I, Kaytan E, )54.8 (A)91.8 (yan N. Childhood nasopharyngeal carcinoma:)]TJ
2.175 -1.25 Td
(from biology to treatment. Lancet Oncol 2003;4:13-21.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Chang )36.8 (YS, )17.7 (T)69.9 (yan )36.8 (YS, Liu ST)73.9 (, )17.7 (T)69.9 (sai MS, Pao CC. Detection of)]TJ
2.1381 -1.25 Td
[(Epstein-Barr virus DNA)-220.2 (sequences in nasopharyngeal carcinoma)]TJ
T*
[(cells by enzymatic DNA)-220.2 (amplification. J Clin Microbiol)]TJ
0 Tc 0 Tw T*
(1990;28:2398-402.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875.1 (V)110.8 (asef MA. Nasopharyngeal carcinoma with emphasis on its)]TJ
2.175 -1.25 Td
[(relationship to EBV)128.8 (. )54.8 (Ann Otol Rhinol Laryngol 1997;106:348-56.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Pachman LM, Litt DL, Rowley )54.8 (AH, et al. Lack of detection of)]TJ
2.175 -1.25 Td
[(enteroviral RNA)-220.2 (or bacterial DNA)-220.2 (in magnetic resonance imaging)]TJ
T*
(directed muscle biopsies from twenty children with active untreated)Tj
T*
[(juvenile dermatomyositis. )54.8 (Arthritis Rheum 1995;38:1513-8.)]TJ
-2.175 -1.25 Td
[(14.)-875.1 (Hu )17.7 (WH, Chen DL, Min HQ. Study of 45 cases of nasopharyngeal)]TJ
2.175 -1.25 Td
[(carcinoma with dermatomyositis. )54.8 (Am J Clin Oncol 1996;19:35-8.)]TJ
-2.175 -1.25 Td
[(15.)-875.1 (Bernard P)110.7 (, Bonnetblanc JM. Dermatomyositis and malignancy)64.8 (. )]TJ
2.175 -1.25 Td
(J Invest Dermatol 1993;100:128S-32S.)Tj
-2.175 -1.25 Td
[(16.)-875.1 (Amerio P)110.7 (, Girardelli CR, Proietto G, et al. Usefulness of)]TJ
2.175 -1.25 Td
(erythrosedimentation rate as tumor marker in cancer associated)Tj
T*
(dermatomyositis. Eur J Dermatol 2002;12:165-9.)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
32 0 obj
<>stream
8;Z\6Min,r#ikr70YcYC%AYN)h7AV&9'5b`Pa2j^HU-PF?tQn"";0%1o8i2bB\sk*
#9LRnG\bIf)6"YZIe*!apX!':Ws#EL[ZO]mRi"03T1h$66gbVQ2;O9"fOAGO(<#6>
T4ogHn4&C,NI#]<=ju8`m<-:hls4^kI\o9`cO5t2=K^F)g*:EGM4gaVKr,S@8qO:Z
T>=L10N?=OG#&r,oo(sFiR1S`o4/CZ@eXT%FH;2r=H4d&ib$Jmq/hh^Of"6pQ^EZ@
T59(
+d0r'GX2KG(KKXlSgMJPGfk3M8R&Mt-km#B6D74('FMSb>JTlsjn,2)Kk$A8GI0<1
ePl5V>Qt2<1uNW~>
endstream
endobj
36 0 obj
[/Indexed/DeviceRGB 255 35 0 R]
endobj
35 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
59 0 obj
<>
endobj
66 0 obj
<>
endobj
77 0 obj
<>
endobj
94 0 obj
<>
endobj
106 0 obj
<>
endobj
76 0 obj
<>
endobj
86 0 obj
<>stream
H\T{PSgO~rɸ֪GiRc:%bJo#EB98"H
1h~VlV>/+{:5TA)#"GDDͱdu9NO=cl^ؙO1XsYV|Zmrz}ɤ_,g>O}To9|Z!+ߠd蓍fKNAA?OfNR5wnLXPJG1Vx[L)
K Q):n/C2RVnT4@(2W&@)|nʟ(hV6
0|#+ȸl(>ѳ[Ss\z߆lv}A%ߐh~ctPj[?YyHA5qY=inOWY}
!} 4u[^? .P"߾8>^H iHACE%( Yl
)G+
l%d1KZsTBQ4FiIr[iz.@yhgNuϝmlF>099&ӐNIݚ<~D[uJ,|ZwmqPH֖wcJA.8E R0ɀg^! DZu$̬ f`f`"ONWmD
%Ddwi
7M$v,tS4\d-;
a<<}9DŽFG A^#S_.N?-(HHkݬh#tp>s/+Lw,{MSXWDu@\;lIc=mۖa)XOz[<]RGrKX*w_Y+\
r\O*7
).!_!>H&
3Th}?S'^ t aZe,͋wx&;gSݹBz<7=\(HK*]tԌ|;Ê<zyg'xEg1u<%0wppaJ Q%OЀv܌k}0^pA3fDiҙ!827Oϒ߅8_'yB }}2nG-R8C3xUI3
%Eśq;J\ofTVsĽwoI8|_Oi/ZLX k+#?7Kubl.t0>.x=DO_v4fw.@+X)H)um50O'Mh +JJ
s̫giop Gؙ̀7PL%o0E@=י)=aA{x@M1lG.N| $,>oR6eRKUQVV#7OJTvb*@O*nHՕ OԶ~L;*"yQmLa
IrIʀA$x~bAű̳nګ}/~k/,G*95vÅЃϖ#(c-t
ʡ
\z)ulKw'-{s}0HN8K9UUlku'm=[@X=
Lj
1LyVխG|QjA~s5
wrh|fhe!9o>aj 4
endstream
endobj
64 0 obj
<>
endobj
85 0 obj
<>stream
H|TPSW777
W{v+*CTo] A@cPQ"P⣸n|*Sunsfs?9cb8_OcS5验VAX֫uF{]B0TtnBLj2\H)v>3^ҥb|w-m/La"1l;(ab/La6aQv0#x9 )TQ{bQNxx'HtiCe7=K\0Kju9+q};~v@vse3L{yQ?<#